These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37989709)

  • 41. Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?
    Shen HM; D'Souza AM; Green IF; Pohar KS; Mortazavi A; Zynger DL
    Hum Pathol; 2015 Sep; 46(9):1367-75. PubMed ID: 26232112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
    Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
    BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
    Reike MJ; de Jong JJ; Bismar TA; Boorjian SA; Mian OY; Wright JL; Dall'Era MA; Kaimakliotis HZ; Lotan Y; Boormans JL; Black PC; Gibb EA
    Urol Oncol; 2024 Jun; 42(6):177.e5-177.e14. PubMed ID: 38480079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer.
    Onishi T; Sekito S; Shibahara T; Yabana T
    Urol Oncol; 2021 Feb; 39(2):132.e1-132.e6. PubMed ID: 32792215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.
    Faiena I; Salmasi A; Mendhiratta N; Lenis AT; Pooli A; Drakaki A; Gollapudi K; Blumberg J; Pantuck AJ; Chamie K
    World J Urol; 2018 Nov; 36(11):1825-1833. PubMed ID: 29752514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM
    Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.
    Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C
    Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Buisan O; Orsola A; Areal J; Font A; Oliveira M; Martinez R; Ibarz L
    Clin Genitourin Cancer; 2017 Feb; 15(1):145-151.e2. PubMed ID: 27364982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lymphovascular invasion predicts poor prognosis in high-grade pT1 bladder cancer patients who underwent transurethral resection in one piece.
    Ukai R; Hashimoto K; Nakayama H; Iwamoto T
    Jpn J Clin Oncol; 2017 May; 47(5):447-452. PubMed ID: 28184446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
    Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
    Martini A; Jia R; Ferket BS; Waingankar N; Plimack ER; Crabb SJ; Harshman LC; Yu EY; Powles T; Rosenberg JE; Pal SK; Vaishampayan UN; Necchi A; Wiklund NP; Mehrazin R; Mazumdar M; Sfakianos JP; Galsky MD
    Cancer; 2019 Sep; 125(18):3155-3163. PubMed ID: 31150110
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy.
    von Landenberg N; Speed JM; Cole AP; Seisen T; Lipsitz SR; Gild P; Menon M; Kibel AS; Roghmann F; Noldus J; Sun M; Trinh QD
    Urol Oncol; 2018 Feb; 36(2):78.e13-78.e19. PubMed ID: 29169845
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study.
    von Rundstedt FC; Mata DA; Kryvenko ON; Shah AA; Jhun I; Lerner SP
    Bladder Cancer; 2017 Jan; 3(1):35-44. PubMed ID: 28149933
    [No Abstract]   [Full Text] [Related]  

  • 58. Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy.
    D'Andrea D; Shariat SF; Soria F; DI Trapani E; Mertens LS; VAN Rhijn BW; Dinney CP; Black PC; Spiess PE; Carrion DM; Pradere B; Tonin E; Pichler R; Filippot R; Mari A; Moschini M;
    Minerva Urol Nephrol; 2023 Aug; 75(4):452-459. PubMed ID: 37314813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
    Zennami K; Sumitomo M; Takahara K; Nukaya T; Takenaka M; Fukaya K; Ichino M; Fukami N; Sasaki H; Kusaka M; Shiroki R
    BJU Int; 2021 Mar; 127(3):332-339. PubMed ID: 32896105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
    PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.